<abstract xmlns="http://www.w3.org/1999/xhtml"><p>Vortioxetine is a novel antidepressant with two mechanisms of action – direct effect on several serotonin receptors and serotonin re-uptake inhibition. It shows antidepressant, anxiolytic and cognitive effects during the treatment of major depressive disorder (MDD). The aim of this article was to summarize the use of vortioxetine in clinical studies and assess the efficacy and tolerability. Most of the studies reported a statistically significant efficacy for vortioxetine versus placebo. In addition, vortioxetine showed efficacy in patients with an inadequate response to selective serotonin re-uptake inhibitors (SSRI) or serotonin-noradrenaline re-uptake inhibitors (SNRI) monotherapy and improved cognitive function in patients with MDD. In these studies, vortioxetine was well tolerated – most common observed adverse effect was nausea – and it was not associated with clinically important changes in laboratory test results or vital signs. Vortioxetine showed a relatively low incidence of sexual dysfunction.</p></abstract>

Vortioxetine is a novel antidepressant with two mechanisms of action – direct effect on several serotonin receptors and serotonin re-uptake inhibition. It shows antidepressant, anxiolytic and cognitive effects during the treatment of major depressive disorder (MDD). The aim of this article was to summarize the use of vortioxetine in clinical studies and assess the efficacy and tolerability. Most of the studies reported a statistically significant efficacy for vortioxetine versus placebo. In addition, vortioxetine showed efficacy in patients with an inadequate response to selective serotonin re-uptake inhibitors (SSRI) or serotonin-noradrenaline re-uptake inhibitors (SNRI) monotherapy and improved cognitive function in patients with MDD. In these studies, vortioxetine was well tolerated – most common observed adverse effect was nausea – and it was not associated with clinically important changes in laboratory test results or vital signs. Vortioxetine showed a relatively low incidence of sexual dysfunction.

Review of a New Multimodal Antidepressant Vortioxetine

Comenius University in Bratislava, Jessenius Faculty of Medicine in Martin and University Hospital Martin, Department of Pharmacology

Biomedical Center Martin, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava

Acta Medica Martiniana

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

{"article-title":"Review of a New Multimodal Antidepressant Vortioxetine"}

Vortioxetine is a novel antidepressant with two mechanisms of action – direct effect on several serotonin receptors and serotonin re-uptake inhibition. It...

Review of a New Multimodal Antidepressant Vortioxetine

Data publikacji: 24 wrz 2016

Zakres stron: 44 - 48

Otrzymano: 26 kwi 2016

Przyjęty: 27 cze 2016

DOI: https://doi.org/10.1515/acm-2016-0011

Słowa kluczowe
vortioxetine, depression, inadequate response, cognitive function, sexual dysfunction

© 2016 Oppa M et al., published by De Gruyter Open

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Review of a New Multimodal Antidepressant Vortioxetine

Data publikacji: 24 wrz 2016

Zakres stron: 44 - 48

Otrzymano: 26 kwi 2016

Przyjęty: 27 cze 2016

DOI: https://doi.org/10.1515/acm-2016-0011

Słowa kluczowevortioxetine, depression, inadequate response, cognitive function, sexual dysfunction

© 2016 Oppa M et al., published by De Gruyter Open

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Słowa kluczowe
vortioxetine, depression, inadequate response, cognitive function, sexual dysfunction